Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

• Main Authors: Marin Veldic (Author), Ahmed T. Ahmed (Author), Caren J. Blacker (Author), Jennifer R. Geske (Author), Joanna M. Biernacka (Author), Kristin L. Borreggine (Author), Katherine M. Moore (Author), Miguel L. Prieto (Author), Jennifer L. Vande Voort (Author), Paul E. Croarkin (Author), Astrid A. Hoberg (Author), Simon Kung (Author), Renato D. Alarcon (Author), Nicola Keeth (Author), Balwinder Singh (Author), William V. Bobo (Author), Mark A. Frye (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment for depression, which may further impact clinical antidepressant treatment rec...